AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1539466 — intervention group
Group type: COMPARATOR
Intervention: Old type B subunit-whole cell cholera vaccine
Number of subjects: 0
Study 3886392 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisone)
Number of subjects: 141
Study 3886392 — intervention group
Group type: COMPARATOR
Intervention: MEV regimen (methotrexate, cyclophosphamide and vincristine)
Number of subjects: 141
Study 3886392 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Number of subjects: 141
Study 3886392 — intervention group
Group type: COMPARATOR
Intervention: MEV regimen
Number of subjects: 141
Study 3886392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 141
Study 31789482 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D (25(OH)D) levels in the lowest tertile (<11 ng/mL)
Number of subjects: 219
Study 31789482 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF-23 levels in the highest tertile (>3750 RU/mL)
Number of subjects: 219
Study 31789482 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PTH levels
Number of subjects: 219
Study 30593883 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype-stratified clinical trial (Steroids in Eosinophil Negative Asthma - SIENA)
Number of subjects: 0
Study 30593883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-specified contingency plans
Number of subjects: 0
Study 27937046 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling in addition to personalized, evidence-based physical therapy treatment
Number of subjects: 120
Study 27937046 — intervention group
Group type: COMPARATOR
Intervention: Personalized, evidence-based physical therapy treatment
Number of subjects: 120
Study 24929431 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 receptor agonist)
Number of subjects: 16
Study 24929431 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (sulfonylurea)
Number of subjects: 16
Study 24929431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets)
Number of subjects: 16
Study 24929431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injections)
Number of subjects: 16
Study 22492085 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg/day
Number of subjects: 62
Study 22492085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day
Number of subjects: 62
Study 22492085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22492085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (1, 6, and 18 hr)
Number of subjects: 62
Study 22492085 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reinforcement
Number of subjects: 62
Study 22492085 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving, mood, withdrawal, and subjective cigarette effects
Number of subjects: 62
Study 19947274 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital acupoint pressure (DAP group)
Number of subjects: 400
Study 19947274 — intervention group
Group type: COMPARATOR
Intervention: Chinese herb medicine of Gentongping (medicine group)
Number of subjects: 400
Study 19947274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DAP and medicine)
Number of subjects: 400
Study 17434847 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide-based therapy
Number of subjects: 64
Study 15309728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 1161
Study 15309728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy combined with hyperthermia or activated carbon particles
Number of subjects: 1161
Study 12002878 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral injections of botulinum toxin
Number of subjects: 49
Study 12002878 — intervention group
Group type: COMPARATOR
Intervention: Bilateral injections of botulinum toxin
Number of subjects: 49
Study 9828734 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI)
Number of subjects: 20
Study 9828734 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet Nebuliser
Number of subjects: 20
Study 9828734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Nebuliser
Number of subjects: 20
Study 9828734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Nebuliser and MDI
Number of subjects: 20
Study 8011011 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 8011011 — intervention group
Group type: COMPARATOR
Intervention: Analgesic medications
Number of subjects: 0
Study 8011011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2735497 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 0
Study 2735497 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 0
Study 812894 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG fractions purified by ion exchange chromatography and specific immunosorbents
Number of subjects: 0
Study 812894 — intervention group
Group type: COMPARATOR
Intervention: IgE fractions
Number of subjects: 0
Study 812894 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 0
Study 31369394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 70
Study 31369394 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 70
Study 31369394 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Caffeinated and Decaffeinated coffee)
Number of subjects: 70
Study 28408243 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day and bevacizumab 15 mg/kg every 21 days
Number of subjects: 109
Study 28408243 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab in T790M-positive patients
Number of subjects: 109
Study 28408243 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab in T790M-negative patients
Number of subjects: 109
Study 28408243 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety analysis of erlotinib and bevacizumab
Number of subjects: 109
Study 25449864 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS applied to the left DLPFC (n=78)
Number of subjects: 117
Study 25449864 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n=39)
Number of subjects: 117
Study 25449864 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 117
Study 23497601 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC (with reduced cathartic preparation and standard bowel preparation)
Number of subjects: 14000
Study 23497601 — intervention group
Group type: COMPARATOR
Intervention: FOBT (biannual for three rounds)
Number of subjects: 14000
Study 23497601 — intervention group
Group type: EXPERIMENTAL
Intervention: OC
Number of subjects: 14000
Study 21473962 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel pretreatment (30 mg after diagnosis + 30 mg at PCI)
Number of subjects: 4100
Study 21473962 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel non-pretreatment (60 mg at PCI)
Number of subjects: 4100
Study 21473962 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (5 or 10 mg daily)
Number of subjects: 4100
Study 19551471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-CHW team
Number of subjects: 613
Study 19551471 — intervention group
Group type: COMPARATOR
Intervention: Usual CC
Number of subjects: 613
Study 17027548 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave insert with retention of the posterior cruciate ligament
Number of subjects: 64
Study 17027548 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized insert with resection of the posterior cruciate ligament
Number of subjects: 64
Study 17027548 — intervention group
Group type: COMPARATOR
Intervention: Flat insert
Number of subjects: 64
Study 17027548 — intervention group
Group type: COMPARATOR
Intervention: Concave insert
Number of subjects: 64
Study 15472839 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPSV23
Number of subjects: 383
Study 15472839 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 383
Study 15472839 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPSV23 in children aged 1-2 years
Number of subjects: 383
Study 15472839 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPSV23 in older children
Number of subjects: 383
Study 15472839 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide booster vaccination
Number of subjects: 383
Study 11226995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosmolar solution of electrolytes (ISE) administered at a volume of 4 mL/kg 3 hours before completing the fasting period
Number of subjects: 40
Study 11226995 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasting period for milk and solids of at least 8 hours
Number of subjects: 40
Study 8989424 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of immunogen (high dose)
Number of subjects: 24
Study 8989424 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of immunogen (low dose)
Number of subjects: 24
Study 8989424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum alone)
Number of subjects: 24
Study 8235847 — intervention group
Group type: EXPERIMENTAL
Intervention: In-situ posterolateral fusion (group I)
Number of subjects: 27
Study 8235847 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal stabilization with the Steffee plate and screw system (group II)
Number of subjects: 27
Study 8235847 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-instrumented posterolateral grafting)
Number of subjects: 27
Study 3122517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol with balloon catheter and oxytocin infusion
Number of subjects: 50
Study 3122517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol with Lamicel cervical dilatator (5 mm)
Number of subjects: 50
Study 3122517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol with Laminaria tent (6 mm)
Number of subjects: 50
Study 29915852 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion with sevoflurane anesthesia (Group S-M)
Number of subjects: 100
Study 29915852 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion with desflurane anesthesia (Group D-M)
Number of subjects: 100
Study 29915852 — intervention group
Group type: COMPARATOR
Intervention: Control group with sevoflurane anesthesia (Group S)
Number of subjects: 100
Study 29915852 — intervention group
Group type: COMPARATOR
Intervention: Control group with desflurane anesthesia (Group D)
Number of subjects: 100
Study 27814413 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Number of subjects: 961
Study 27814413 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 961
Study 24472401 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Number of subjects: 28
Study 24472401 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ)
Number of subjects: 28
Study 24472401 — intervention group
Group type: EXPERIMENTAL
Intervention: new combined formulation (olmesartan medoxomil + HCTZ)
Number of subjects: 28
Study 24472401 — intervention group
Group type: COMPARATOR
Intervention: co-administration of separate tablets (reference drugs)
Number of subjects: 28
Study 22334811 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label fluoxetine (FLX)
Number of subjects: 60
Study 22334811 — intervention group
Group type: COMPARATOR
Intervention: Laboratory monitoring
Number of subjects: 60
Study 21102998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg (GBX)
Number of subjects: 55
Study 21102998 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (ZOL)
Number of subjects: 55
Study 21102998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 55
Study 18203893 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g EPA plus high-oleic sunflower oil (HOS)
Number of subjects: 17
Study 18203893 — intervention group
Group type: COMPARATOR
Intervention: HOS only (placebo)
Number of subjects: 17
Study 16437727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum MIYAIRI 588 strain (CBM)
Number of subjects: 35
Study 16437727 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, clarithromycin, lansoprazole (Group 1)
Number of subjects: 35
Study 12939213 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab treatment (n=1052)
Number of subjects: 2082
Study 12939213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abciximab treatment, n=1030)
Number of subjects: 2082
Study 10999156 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GMCSF) 150 mcg subcutaneously 24 hours prior to vaccination
Number of subjects: 16
Study 10999156 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard three doses of 40 mcg hepatitis B vaccine monthly
Number of subjects: 16
Study 8697829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.75 mg/kg/d for up to 4 weeks with gradual reduction over an additional 2 weeks)
Number of subjects: 70
Study 8697829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8697829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 70
Study 8697829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Prednisone and Placebo)
Number of subjects: 70
Study 1834707 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise sealant (3M)
Number of subjects: 62
Study 1834707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealite sealant (Kerr)
Number of subjects: 62
Study 1834707 — intervention group
Group type: COMPARATOR
Intervention: Delton sealant (Johnson & Johnson)
Number of subjects: 62
Study 7329877 — intervention group
Group type: EXPERIMENTAL
Intervention: Theograd
Number of subjects: 8
Study 7329877 — intervention group
Group type: EXPERIMENTAL
Intervention: Theodur
Number of subjects: 8
Study 7329877 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolair‐SR
Number of subjects: 8
Study 7329877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rona‐slophylline
Number of subjects: 8
Study 30321958 — intervention group
Group type: EXPERIMENTAL
Intervention: MOK-cast
Number of subjects: 107
Study 30321958 — intervention group
Group type: COMPARATOR
Intervention: Wrap
Number of subjects: 107
Study 28083698 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT-IR-FBP
Number of subjects: 151
Study 28083698 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT-MBIR
Number of subjects: 151
Study 28083698 — intervention group
Group type: COMPARATOR
Intervention: CECT
Number of subjects: 151
Study 25563677 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric + basketball training (PT)
Number of subjects: 16
Study 25563677 — intervention group
Group type: COMPARATOR
Intervention: Basketball training (BT)
Number of subjects: 16
Study 24247275 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) including pharmacist-led medication reconciliation, patient education, collaborative care, and voice messaging.
Number of subjects: 253
Study 24247275 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for clopidogrel adherence.
Number of subjects: 253
Study 24247275 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for statins adherence.
Number of subjects: 253
Study 24247275 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for ACEI/ARB adherence.
Number of subjects: 253
Study 24247275 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for β-blockers adherence.
Number of subjects: 253
Study 24247275 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group adherence.
Number of subjects: 253
Study 24247275 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) for BP and LDL-C level goals achievement.
Number of subjects: 253
Study 22947594 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate long-acting injection (PP-LAI)
Number of subjects: 3173
Study 19051699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15187573 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (high-tissue penetrating ACE inhibitor)
Number of subjects: 30
Study 15187573 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (low-tissue penetrating ACE inhibitor)
Number of subjects: 30
Study 15212611 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 15212611 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine with lithium or valproate
Number of subjects: 0
Study 10489384 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg orally)
Number of subjects: 15
Study 10489384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8598755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 98
Study 8598755 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy with operative cholangiography
Number of subjects: 98
Study 1945319 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom programs with varying threshold determinations (2 to 15 times)
Number of subjects: 30
Study 1945319 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs that determine thresholds only twice at a given location
Number of subjects: 30
Study 1945319 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimating global fluctuation
Number of subjects: 30
Study 7021041 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (500 mg, orally)
Number of subjects: 8
Study 7021041 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (100 mg, orally) plus carbidopa (35 mg, orally) after pretreatment with carbidopa (50 mg every 6 h for four doses)
Number of subjects: 8
Study 7021041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31833322 — intervention group
Group type: EXPERIMENTAL
Intervention: Parthenogenetic species with swimming setae
Number of subjects: 111
Study 31833322 — intervention group
Group type: COMPARATOR
Intervention: Sexual species
Number of subjects: 111
Study 31833322 — intervention group
Group type: EXPERIMENTAL
Intervention: Species with swimming setae
Number of subjects: 111
Study 31833322 — intervention group
Group type: EXPERIMENTAL
Intervention: Species without swimming setae
Number of subjects: 111
Study 31833322 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental variables (water temperature, pH, elevation)
Number of subjects: 111
Study 29940864 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 186
Study 29940864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Number of subjects: 186
Study 29940864 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 186
Study 27188907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (HFD)
Number of subjects: 7
Study 27188907 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal after HFD
Number of subjects: 7
Study 27188907 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber diet (Control)
Number of subjects: 7
Study 24472224 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination tablet formulations of azithromycin and chloroquine (AZCQ) administered at approximately 30 mg/kg AZ and 10 mg/kg CQ once daily for 3 days in children.
Number of subjects: 0
Study 24472224 — intervention group
Group type: COMPARATOR
Intervention: Two AZCQ tablets (AZ/CQ 250/155 mg per tablet) in adults.
Number of subjects: 0
Study 24472224 — intervention group
Group type: COMPARATOR
Intervention: Individual commercial tablets of azithromycin 500 mg and chloroquine 300 mg in adults.
Number of subjects: 0
Study 22318278 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB at 2, 4, and 6 months with routine vaccines
Number of subjects: 1885
Study 22318278 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB at 2, 4, and 6 months without routine vaccines
Number of subjects: 1885
Study 22318278 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB with routine vaccines at 2, 3, and 4 months
Number of subjects: 1885
Study 22318278 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccines alone at 2, 3, and 4 months
Number of subjects: 1885
Study 22318278 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB doses administered alone
Number of subjects: 1885
Study 22318278 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccines given alone
Number of subjects: 1885
Study 22318278 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB and routine vaccines administered together
Number of subjects: 1885
Study 20705156 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg misoprostol
Number of subjects: 176
Study 20705156 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg misoprostol
Number of subjects: 176
Study 17337887 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + extended-release dipyridamole (DP)
Number of subjects: 20000
Study 17337887 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20000
Study 17337887 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20000
Study 17337887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20000
Study 17337887 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of stroke, myocardial infarction or vascular death
Number of subjects: 20000
Study 17337887 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite + congestive heart failure, new-onset diabetes, other designated occlusive vascular events, any death, stroke subtype by TOAST criteria, Mini Mental State Examination score
Number of subjects: 20000
Study 17337887 — intervention group
Group type: EXPERIMENTAL
Intervention: Major hemorrhagic events
Number of subjects: 20000
Study 15365788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 20
Study 15365788 — intervention group
Group type: COMPARATOR
Intervention: l-dopa
Number of subjects: 20
Study 15365788 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 20
Study 12122551 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg folic acid
Number of subjects: 70